Oversubscribed Shortfall Offer & Placement raise 1.75m

Key points

• Oversubscribed Shortfall Offer raises $1.75m
• Funds to support China expansion
• FDA 510(k) clearance for BMD technology

Full summary

Curvebeam AI Limited (ASX: CVB) has announced the results of its Shortfall Offer under its share purchase plan, raising a total of $1.75m. The offer, which was oversubscribed, will support the company's expansion into the China market, including sales and marketing expenses, research and development costs, supply chain preparations, and working capital. The funds will also contribute to the FDA 510(k) clearance of the company's CT-based Bone Mineral Density technology, providing a strong regulatory foundation for future strategies.

Outlook

Curvebeam AI Ltd plans to integrate bone quality assessment into its imaging platforms and expand commercial opportunities across China, the United States, and other international markets.